HDAC2 and neoplasm: For HDACs with a broader deacetylation specificity than SIRT1, such as HDAC1 and HDAC2, no somatic mutations in tumours have been described, but a dysregulated expression seems to be a common feature of human neoplasia (Gibbons, 2005).